Repligen Completes Acquisition of BioLife Solutions Expanding Cell Therapy Presence
News related to:Repligen Corporation · 2 min read
WALTHAM, Mass., Oct. 06, 2026 /CourierPR/ -- Repligen Corporation has completed its acquisition of BioLife Solutions, Inc., a company that develops and supplies cell processing tools and services for the cell and gene therapy market. This move is expected to significantly bolster Repligen’s presence in the rapidly growing cell therapy sector.
Repligen, a life sciences company known for its bioprocessing technology leadership, expressed excitement about the acquisition.
BioLife’s products, notably led by CryoStor®, support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. This integration will allow Repligen to benefit from BioLife’s trusted customer relationships and global reach, particularly in the Asia Pacific region. Conversely, BioLife will gain from Repligen’s broader market presence and advanced bioprocessing technologies.
In the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock. The deal is expected to have a significant impact on Repligen’s 2026 financial outlook, though the exact details will be shared in the upcoming third quarter 2026 earnings call.
Repligen’s second quarter revenue for 2026 was reported at $204 million, marking a 12% year-over-year increase as reported and a 13% increase on an organic basis. This financial performance underscores the company’s robust growth trajectory and its strategic positioning in the biopharmaceutical industry.
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company’s focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Its corporate headquarters are located in Waltham, Massachusetts, and the majority of its manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands, and Sweden.
The acquisition of BioLife Solutions is part of Repligen’s broader strategy to expand its portfolio and enhance its capabilities in the cell therapy market. BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering. BioLife’s differentiated biopreservation media portfolio, led by CryoStor®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call. The company’s financial performance and strategic positioning in the biopharmaceutical industry are expected to be further enhanced by this acquisition.
The transaction is expected to have a significant impact on Repligen’s 2026 financial outlook, though the exact details will be shared in the upcoming third quarter 2026 earnings call. The combined entity aims to leverage the strengths of both organizations to drive innovation and deliver value to patients, customers, and shareholders.